CN110204589A - Seed of feather cockscomb effective component, extracting method and its application in terms of preparing nerve protection medicine - Google Patents
Seed of feather cockscomb effective component, extracting method and its application in terms of preparing nerve protection medicine Download PDFInfo
- Publication number
- CN110204589A CN110204589A CN201910572816.4A CN201910572816A CN110204589A CN 110204589 A CN110204589 A CN 110204589A CN 201910572816 A CN201910572816 A CN 201910572816A CN 110204589 A CN110204589 A CN 110204589A
- Authority
- CN
- China
- Prior art keywords
- seed
- feather cockscomb
- compound
- methanol
- effective component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 240000008365 Celosia argentea Species 0.000 title claims abstract description 46
- 235000000722 Celosia argentea Nutrition 0.000 title claims abstract description 45
- 239000003814 drug Substances 0.000 title claims abstract description 13
- 230000004224 protection Effects 0.000 title claims abstract description 11
- 210000005036 nerve Anatomy 0.000 title claims abstract description 7
- 238000000034 method Methods 0.000 title claims description 12
- 229930182470 glycoside Natural products 0.000 claims abstract description 45
- SUSQOBVLVYHIEX-UHFFFAOYSA-N o-phenylene-diaceto-nitrile Natural products N#CCC1=CC=CC=C1 SUSQOBVLVYHIEX-UHFFFAOYSA-N 0.000 claims abstract description 25
- -1 benzene acetonitrile glycosides compound Chemical class 0.000 claims abstract description 23
- 150000001875 compounds Chemical class 0.000 claims abstract description 22
- 150000002338 glycosides Chemical class 0.000 claims abstract description 22
- GXWUEMSASMVWKO-GNLHUFSQSA-N (4as,6ar,6as,6br,10s,12ar,14br)-10-[(2s,3r,4s,5s)-4,5-dihydroxy-3-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid Chemical compound O([C@@H]1[C@@H](O)[C@@H](O)CO[C@H]1O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CCC2C1(C)C)C)(C)CC[C@]1(CCC(C[C@@H]14)(C)C)C(O)=O)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GXWUEMSASMVWKO-GNLHUFSQSA-N 0.000 claims abstract description 20
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 230000036541 health Effects 0.000 claims abstract description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 87
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 43
- 235000019441 ethanol Nutrition 0.000 claims description 20
- 238000000605 extraction Methods 0.000 claims description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 15
- 239000000469 ethanolic extract Substances 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 11
- 238000010828 elution Methods 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 230000004770 neurodegeneration Effects 0.000 claims description 7
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 7
- 238000010898 silica gel chromatography Methods 0.000 claims description 6
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 claims description 5
- 239000012453 solvate Substances 0.000 claims description 5
- 238000004809 thin layer chromatography Methods 0.000 claims description 5
- 239000002250 absorbent Substances 0.000 claims description 3
- 230000002745 absorbent Effects 0.000 claims description 3
- 238000013461 design Methods 0.000 claims description 3
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 3
- 230000014759 maintenance of location Effects 0.000 claims description 3
- 238000004064 recycling Methods 0.000 claims description 3
- 239000011347 resin Substances 0.000 claims description 3
- 229920005989 resin Polymers 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 2
- 238000002474 experimental method Methods 0.000 abstract description 10
- GQMMRLBWXCGBEV-YVMONPNESA-N (nz)-n-[(3-nitrophenyl)methylidene]hydroxylamine Chemical compound O\N=C/C1=CC=CC([N+]([O-])=O)=C1 GQMMRLBWXCGBEV-YVMONPNESA-N 0.000 abstract description 8
- 210000002569 neuron Anatomy 0.000 abstract description 5
- 230000001681 protective effect Effects 0.000 abstract description 5
- 230000004792 oxidative damage Effects 0.000 abstract 1
- 229940125782 compound 2 Drugs 0.000 description 17
- 229940125904 compound 1 Drugs 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 13
- 229910052739 hydrogen Inorganic materials 0.000 description 13
- 239000001257 hydrogen Substances 0.000 description 13
- 229910052799 carbon Inorganic materials 0.000 description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 8
- 230000006907 apoptotic process Effects 0.000 description 7
- 239000006285 cell suspension Substances 0.000 description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 7
- 230000003834 intracellular effect Effects 0.000 description 7
- 238000001228 spectrum Methods 0.000 description 7
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 229960001031 glucose Drugs 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 108010087230 Sincalide Proteins 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 238000010609 cell counting kit-8 assay Methods 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 230000001079 digestive effect Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 4
- 230000001464 adherent effect Effects 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000001052 heteronuclear multiple bond coherence spectrum Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 229930182493 triterpene saponin Natural products 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 241000219317 Amaranthaceae Species 0.000 description 2
- 102000014461 Ataxins Human genes 0.000 description 2
- 108010078286 Ataxins Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010008025 Cerebellar ataxia Diseases 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000003912 environmental pollution Methods 0.000 description 2
- 238000005570 heteronuclear single quantum coherence Methods 0.000 description 2
- 238000000990 heteronuclear single quantum coherence spectrum Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 241000201841 Celosia Species 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 244000048738 European olive Species 0.000 description 1
- 108010040476 FITC-annexin A5 Proteins 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 241000475481 Nebula Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 229960002246 beta-d-glucopyranose Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003109 clavicle Anatomy 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- LHVVWWADJUJFEH-HKNOZQPISA-N hexadecanoic acid (9Z,12Z)-octadeca-9,12-dienoic acid octadecanoic acid (9Z,12Z,15Z)-octadeca-9,12,15-trienoic acid (Z)-octadec-9-enoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCC\C=C/C\C=C/CCCCCCCC(O)=O.CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O LHVVWWADJUJFEH-HKNOZQPISA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000008954 quail grass Nutrition 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000036301 sexual development Effects 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
- A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Botany (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Psychiatry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to seed of feather cockscomb effective components, which is characterized in that including Oleanolic triterpenic glycoside class compound and/or benzene acetonitrile glycosides compound, the structural formula of Oleanolic triterpenic glycoside class compound is as follows:；The structural formula of benzene acetonitrile glycosides compound is as follows:
Description
Technical field
The invention belongs to pharmaceutical technologies, and in particular to seed of feather cockscomb effective component (Oleanolic triterpenic glycoside class and/
Or benzene acetonitrile glycosides compound), extracting method and its application in terms of preparing nerve protection medicine or health care product.
Background technique
Neurodegenerative disease is characterized in the loss of the progressive damage and neuron of nerve cell, with pushing away for time
It moves and deteriorates, lead to movement or cognitive impairment, belong to disabling for a kind of progress sexual development, serious pernicious complicated disease
Disease.Common neurodegenerative disease includes Alzheimer disease (AD), amyotrophic lateral sclerosis clavicle sclerosis (ALS), Parkinson's disease
(PD), Huntington disease (HD) and spinocerebellar ataxia (SCA).Although the pathology of neurodegenerative disease are still unclear
Chu, many reports have revealed that oxidative stress plays key effect, lead to active oxygen radical (ROS) largely generation and DNA
Oxidation.Usually since old and mitochondria dysfunction generates excessive active oxygen in neurodegenerative disease patient, these
Active oxygen further damages albumen and DNA, and after Apoptosis damages other cells, ROS is largely discharged, to draw
Cytotoxicity domino effect is sent out, and ROS can cause neurotransmission disorder, and gradually increase and suffer from neurodegenerative disease
Risk.The evidence of accumulation shows that the Chinese medicine with neuroprotection can be by inhibiting oxidative stress reduction to suffer from neurological
The risk of property disease.
The seed of feather cockscomb (Celosiae semen) is the feather cockscomb of Amaranthaceae (Amaranthaceae) plant feather cockscomb category (Celosia)
(Ce losia argenteaL. dry mature seed) records kind for pharmacopeia.Seed of feather cockscomb bitter, cold nature, return liver warp,
Major function removing nebula, clearing liver-fire, Compendium of Material Medica, which records the seed of feather cockscomb, has " beneficial brains ".Cauline leaf, the Miao Jieke of feather cockscomb
It is edible, it is the good edible wild vegetables of quality.Modern pharmacological studies have shown that the seed of feather cockscomb has anti-oxidant, liver protection, anti-inflammatory, drop blood
It is sugared, antitumor, anti-infective, treatment cataract, mitosis the effects of.Its main chemical component has saponin(e, cyclic peptide, biology
Alkali, phenols etc., seed of feather cockscomb resource distribution is in China's most area, while in other torrid zones, subtropical countries or Area distribution
Also very wide.For developing efficient, low price protection neurologic agent or health care product, " the difficulty of getting medical service, the high cost of getting medical treatment " is solved with important
Meaning.Currently, the relevant report for not thering is the seed of feather cockscomb to apply in patron saint through aspect.
Summary of the invention
Present invention aims to overcome that prior art defect, provide it is a kind of by Oleanolic triterpenic glycoside class and/or
The seed of feather cockscomb effective component of benzene acetonitrile glycosides compound composition, extracting method and its answering in terms of preparing nerve protection medicine
With.
To achieve the above object, the present invention adopts the following technical scheme:
Seed of feather cockscomb effective component comprising Oleanolic triterpenic glycoside class compound and/or benzene acetonitrile glycosides compound, neat pier
The structural formula of tartaric acid type triterpene saponin componds is as follows:
；
The structural formula of benzene acetonitrile glycosides compound is as follows:
。
The preparation method of above-mentioned seed of feather cockscomb effective component comprising following steps:
1) seed of feather cockscomb that crushed or the stir-fry seed of feather cockscomb are subjected to homogenate extraction with 20-50% ethyl alcohol, extracting solution is concentrated to get extraction
Object medicinal extract；Extract medicinal extract is dispersed in water, is adsorbed with macroporous absorbent resin, water, 20% ethyl alcohol and 60% second are then successively used
Alcohol gradient elution collects 20% ethanol eluate, solvent is recovered under reduced pressure, obtains 20% ethanol extract A；60% ethanol eluate is collected,
Solvent is recovered under reduced pressure, obtains 60% ethanol extract B；
2) by 20% ethanol extract A through thin-layer chromatography silica gel column chromatography, select volume ratio 8:1 methylene chloride and methanol solvate into
Row elution, recycling design obtain flow point；HPLC chromatogram method is partly prepared again, is eluted with 20% methanol-water, and retention time is
24min obtains benzene acetonitrile glycosides compound；
3) 60% ethanol extract B is selected into methanol-water solvent system, successively respectively with 15% first through the open column of MCIGELCHP20
Alcohol, 40% methanol, 50% methanol, 60% methanol, 100% methanol elution gradient, obtained component are successively denoted as: B-1, B-2, B-3, B-
4,B-5；By component B-5 through thin-layer chromatography silica gel column chromatography, the methylene chloride of volume ratio 5:1 and methanol solvate is selected to be washed
It takes off to get Oleanolic triterpenic glycoside class compound.
The preparation method of above-mentioned seed of feather cockscomb effective component, specifically, in step 1), homogenate extraction 2-3 times, homogenate extraction
When every 1 g seed of feather cockscomb or fry the 20-50% ethyl alcohol of seed of feather cockscomb addition 5-10mL, the time of each homogenate extraction is 3-
10min。
The present invention provides application of the above-mentioned seed of feather cockscomb effective component in terms of preparing nerve protection medicine or health care product.
The present invention also provides above-mentioned seed of feather cockscomb effective components in preparation treatment neurodegenerative disease drug or health care
Application in terms of product.
Compared to the prior art, beneficial effects of the present invention:
1) these two types of compound structures of the present invention are stablized, and are belonging respectively to Oleanolic triterpenic glycoside class compound and benzene acetonitrile glycosides
Class compound, and it extracts raw material from the feather cockscomb for being grown on Plain or hillside bank.Feather cockscomb is general to be distributed in China's most area,
Resource very abundant.Working condition of the present invention is mild, and experimental procedure is few, and technical difficulty is small, and production cost is low, and environmental pollution is small；
Simultaneously its abundant raw material, belong to natural reproducible resource；Extraction and separation technology difficulty is small, and solvent is recyclable, separates filler
It can be used repeatedly, not will cause ecological environmental pollution；
2) it is found through experiment that: the present invention includes Oleanolic triterpenic glycoside class compound and/or benzene acetonitrile glycosides compound
Seed of feather cockscomb effective component has good protective effect to t-BHP inducing nerve cell NSC34 damage model, shows as without thin
Born of the same parents' poison toxicity improves cell viability, reduces intracellular ROS level, reduces apoptosis rate.
Detailed description of the invention
Fig. 1 is Oleanolic triterpenic glycoside class compound 113C H NMR spectroscopy；
Fig. 2 is Oleanolic triterpenic glycoside class compound 11H H NMR spectroscopy；
Fig. 3 is the hsqc spectrum of Oleanolic triterpenic glycoside class compound 1；
Fig. 4 is that the HMBC of Oleanolic triterpenic glycoside class compound 1 is composed；
Fig. 5 is that the NOESY of Oleanolic triterpenic glycoside class compound 1 is composed；
Fig. 6 is that the HR-TOF-MS of Oleanolic triterpenic glycoside class compound 1 is composed；
Fig. 7 is benzene acetonitrile glycosides compound 213C H NMR spectroscopy；
Fig. 8 is benzene acetonitrile glycosides compound 21H H NMR spectroscopy；
Fig. 9 is the hsqc spectrum of benzene acetonitrile glycosides compound 2；
Figure 10 is that the HMBC of benzene acetonitrile glycosides compound 2 is composed；
Figure 11 is that the HR-TOF-MS of benzene acetonitrile glycosides compound 2 is composed；
Figure 12 is the INFRARED SPECTRUM of benzene acetonitrile glycosides compound 2；
Figure 13 is the intracellular ROS imaging results of NSC34.
Specific embodiment
Technical solution of the present invention is further discussed in detail with reference to embodiments, but protection scope of the present invention
It is not limited thereto.
In following embodiments, unless otherwise specified, methanol, ethyl alcohol refer to concentration of volume percent.
Oleanolic triterpenic glycoside class compound of the present invention, benzene acetonitrile glycosides compound extraction raw material be the seed of feather cockscomb
(Celosiae semen), in October, 2015 buying are reflected in Yuzhou of Henan medicinal material market by He'nan University professor Yuan Wangjun
Fixed, specimen storage is in pharmaceutical college, He'nan University specimen museum.
Embodiment 1
Seed of feather cockscomb effective component comprising Oleanolic triterpenic glycoside class compound and/or benzene acetonitrile glycosides compound, neat pier
The structural formula of tartaric acid type triterpene saponin componds 1 is as follows:
；
The structural formula of benzene acetonitrile glycosides compound 2 is as follows:
。
The preparation method of above-mentioned seed of feather cockscomb effective component, specifically comprises the following steps:
1) it by the smashed seed of feather cockscomb or fries seed of feather cockscomb 9.5kg and carries out homogenate extraction 3 times with 50% ethyl alcohol 50L (first time is flash
Extract 3 min, second of 5 min of homogenate extraction, 5 min of third time homogenate extraction), after homogenate extraction, filtering, extracting solution
It is concentrated to get extract medicinal extract；Extract medicinal extract is dispersed in water, is adsorbed with HPD100 macroporous absorbent resin, is then successively used
Water, 20% ethyl alcohol, 60% ethanol gradient elution collect 20% ethanol eluate, solvent are recovered under reduced pressure, obtains 20% ethanol extract A；It receives
Collect 60% ethanol eluate, solvent is recovered under reduced pressure, obtains 60% ethanol extract B；
2) 20% ethanol extract A 20mL methanol is dissolved, silica gel mixed sample, through thin-layer chromatography silica gel column chromatography, selects volume ratio 8:
1 methylene chloride-methanol solvent is eluted, and recycling design obtains flow point；HPLC chromatogram method is partly prepared again, with 20% first
Alcohol-water elution, flow velocity 8 ml/min, retention time 24min obtain benzene acetonitrile glycosides compound, are denoted as compound 2
(35mg)；
3) 60% ethanol extract B is suspended in 150mL water, through the open column of MCIGELCHP20, selects methanol-water solvent system,
Successively 5 are obtained according to eluting order with 15% methanol, 40% methanol, 50% methanol, 60% methanol, 100% methanol elution gradient respectively
A component, is successively denoted as: B-1, B-2, B-3, B-4, B-5.Component B-5 15mL methanol is dissolved, silica gel mixed sample, through thin layer color
Silica gel column chromatography is composed, selects the methylene chloride of volume ratio 5:1 and methanol solvate to be eluted, obtains one-component, i.e. olive
Acid type triterpene saponin componds (56mg), are denoted as compound 1.
It is following to give the correlation test data (specific visible Fig. 1 to 12) of compound 1 and compound 2.
Compound 1
White powder is soluble in methanol, 826.4575 [M+NH of TOF-MS:m/z4]+, 831.4112 [M+Na]+, 847.3884
[M+K]+.UV (MeOH), which is shown at 203nm, apparent ultraviolet absorption peak.1H NMR and13C NMR data is referring to table 1.
The 100MHz carbon spectrum and 400MHz hydrogen modal data ownership of 1 compound 1 of table
Compound 2
White powder is soluble in methanol.HR-TOF-MS:m/z 440.1546[M-H]-, 476.1310 [M+Cl]-,
486.1600 [M+HCOOH-H]-.IR (KBr) ν max:3425,2923,2254,1591,1512,1236；UV (MeOH) is aobvious
Showing at 220nm has apparent ultraviolet absorption peak.1H NMR and13C NMR data is referring to table 2.
The 100MHz carbon spectrum and 400MHz hydrogen modal data of 2 compound 2 of table
1 structure elucidation of compound.
White powder is soluble in methanol, 826.4575 [M+NH of HR-TOF-MS:m/z4]+, 831.4112 [M+Na]+,
847.3884[M+K]+, as shown in Figure 6.UV (MeOH), which is shown at 203nm, apparent UV absorption.1H-NMR(CD3OD)
It is provided in spectrum, aldehyde radical hydrogen signal δ a 9.44(1H, s, H-23)；Two sugared end group hydrogen signal δ 4.50(1H, d, J=
7.5Hz, H-Xyl-1), 4.38(1H, d, J=8.0Hz, H-GlcA-1)；One alkene hydrogen signal δ 5.24(1H, s, H-12)；Six
A methyl proton signal δ 0.81(3H, s, H-29), 0.89(3H, s, H-30), 0.93(3H, s, H-26) and, 1.16(3H, s, H-
27), 1.28(3H, s, H-25), 1.32(3H, s, H-24).13C-NMR(CD3OD) in spectrum, low field area provides three carbonyl carbon letters
Number δ 208.8(C-23), 181.8(C-28), 171.1(C-GlcA-6)；Alkene carbon signal δ 145.3(C-13), 123.4(C-
12) and two sugar end group carbon signal δ 105.7(C-Xyl-1), 104.6(C-GlcA-1).Composed by HSQC and HMBC, by carbon and
Hydrogen signal is belonged to, HMBC spectrum in provide, δ 2.83(H-18 in parent nucleus) and 181.8(C-28), 145.3(C-13),
It is 123.4(C-12) long-range related, δ 1.16(H-27) it is remote with δ 24(C-11) to long-range related, the δ 5.24(H-12 of 145.3(C-13))
Cheng Xiangguan, thus it is speculated that C-28 is carbonyl carbon, and C-12,13 are olefinic double bonds, δ 4.24(H-2) with the long-range phase of 37(C-10), 55(C-4)
Close, thus it is speculated that C-2 is optionally substituted by a hydroxyl group, δ 9.44(H-23) it is long-range related to 55(C-4), 11.7(C-24), δ 3.85 (H-3) and
It is 208.8(C-23) long-range related, so speculate that C-23 is replaced by aldehyde radical, the long-range phase of δ 3.85 (H-3) and 104.6(C-GlcA-6)
Close, so glucose and C-3 form glycosidic bond, δ 3.50(H-GlcA-3) it is long-range related to 105.7(C-Xyl-1), so xylose connects
Meet the C-3 in glucose.By comparing carbon spectrum and hydrogen modal data with known compound, thus it is speculated that the knot of the compound and feather cockscomb glycosides L
Structure is similar, from MASS SPECTRAL DATA ANALYSIS, compound CH more than feather cockscomb glycosides L2, in HMBC spectrum, δ 171.1(C-GlcA-6)
It is long-range related to the hydrogen signal 3.75(s of-OCH3), so speculating the carboxylic acid structure esterification on glucose, main HMBC phase
OFF signal, as shown in Figures 1 to 4.From NOESY it can be seen that, H-C (2) and H-C (3), Me(24) and Me(25) there are NOE effects
Answer, H-C (3) and Me(24) and Me(25) there are NOE effect, there are NOE effect, Me(25 for H-C (5) and CHO (23)) and Me
(26) there are NOE effect, CH2(19) and Me(27) and Me(29) there are NOE effects, it is possible thereby to be inferred to H-C (2), H-C
(3), Me(24), Me(25) and Me(26) be in β key, CH2(19), Me(27) and Me(29) in α key.Main NOESY phase
OFF signal is shown in Fig. 5.Through scifinder data base querying, thus it is speculated that compound 1 is noval chemical compound, and structure is 2 alpha-hydroxy-2 3- aldehyde
- 3 α-O- of base [β-D- xylopyranosyl-(1 → 3)-β-D- glucopyranose methyl esters]-oleanolic acid.Nuclear magnetic data is shown in Table 1.
2 structure elucidation of compound.
White powder is soluble in methanol.HR-TOF-MS:m/z 440.1546[M-H]-, 476.1310 [M+Cl]-,
486.1600 [M+HCOOH-H]-, as shown in figure 11.IR (KBr) ν max:3425,2923,2254,1591,1512,1236；
UV (MeOH), which is shown at 220nm, apparent UV absorption.1H-NMR(CD3OD it) is provided in spectrum, two sugared terminal hydrogen letters
Numberδ4.72(1H br. d,J=1.2Hz, H-Rha-1), 4.88(1H, d,J=7.6Hz, H-Glc-1)；Four aromatic signalsδ7.32(2H, d,J=8.4Hz, H-2,6), 7.12(1H, d,J=8.4Hz, H-3,5), are shown in Fig. 7.13C-NMR(CD3OD it) is given in spectrum
Out, six fragrant carbon signalsδ126.0(C-1), 130.3(C-2,6), 118.3(C-3,5), 158.6(C-4)；Two sugared ends
Base carbon signalδ102.2(C-Glc-1), 102.1(C-Rha-1)；One itrile group carbon signalδPpm:119.9(C-8)；One secondary carbon
Signalδ22.7(C-7), see Fig. 8.It is composed by HSQC and HMBC, carbon and hydrogen signal is belonged to, provided in HMBC spectrum,
It can see glucose end group hydrogen signalδ4.88(1H, d,J=7.6Hz, H-Glc-1) withδIt is 158.6(C-4) long-range related, so
Glucose is connected in C-4；The end group hydrogen signal of rhamnoseδ4.72(1H, br.d,J=1.2Hz, H-Rha-1) withδ67.8(C-
Glc-6) long-range related, so rhamnose is connected in glucose C-6；Hydrogen signal on C-7δ3.85(s) withδ126.0(C-1),
130.3(C-2), 119.9(C-8) it is long-range related, so speculating-a CH2CN structure is connected in C-1, and main HMBC is related
Signal, such as Fig. 9,10.In conjunction with the infrared spectroscopy of Figure 12, absorption peak 2254 is the characteristic peak of cyano.It is looked into through scifinder database
It askes, thus it is speculated that compound 10 is noval chemical compound: structure is benzene acetonitrile -4-O-α- L- rhamnopyranose-(1 → 6)-O-β- D- pyrans Portugal
Polyglycoside.Nuclear magnetic data is shown in Table 2.
Seed of feather cockscomb effective component (compound 1 and compound 2) causes the protective effect of NSC34 cellular damage real t-BHP
It tests.
1 .1 laboratory apparatus and material.
6,12,24,96 porocyte culture plates (CoStar. Inc.), NSC34 cell are purchased from U.S.'s ATCC cell bank,
Biofuge stratos high speed low temperature centrifugal machine (Thermo Inc.), 41 type microscope of CKX (OLYMPUS Inc.), HEPA
100 type carbon dioxide incubator of Class (Thermo Inc.) YXQ-LS-50 full-automatic digital display steam sterilizer of II type (Shanghai
Bo Xun Industrial Co., Ltd.), flow cytometer BD LSR Fortessa X-20, Laser Scanning Confocal Microscope Inverted Zeiss
LSM 880 Confocal, microplate reader PHERAstar FS, Li-Cor imager Odyssey CLx., fetal calf serum are purchased from PAA
1640 culture medium of Laboratories GmbH, RPMI is purchased from Invitrogen Inc., and trypsase is purchased from Amresco
Inc.CKK-8, t-BPH, CellROX, Heochest33342 are purchased from SIGMA.
1.2 CCK-8 methods detect NSC34 cellulotoxic experiment
Experimental method:
1) the NSC34 cell in good condition in exponential phase of growth is taken, addition 0.25% tryptic digestive juice digestion makes adherent thin
Born of the same parents fall off, and count 1 × 105A/ml, is made cell suspension；
2) take cell suspension inoculation on 96 orifice plates, 100 holes μ l/ set 37 DEG C of constant temperature, 5%CO2It is cultivated 24 hours in incubator；
3) various concentration test medicine is added, 10 holes μ l/ (final concentration of: 2,5,10,25,50,100 μM) is cultivated 24 hours；
4) CCK-8 of 10 μ l is added in every hole, is incubated for 1h in the incubator；
5) it being measured with microplate reader, measurement wavelength is 450nm, calculate inhibiting rate:
Inhibiting rate=[A (control)-A (sample)]/[A (control)-A (blank)] × 100%.
Experimental result such as following table.The result shows that compound 1 and compound 2 are safe to NSC34 cell.
1.2 CCK-8 methods detect cell viability experiment
Experimental method:
1) the NSC34 cell in good condition in exponential phase of growth is taken, addition 0.25% tryptic digestive juice digestion makes adherent thin
Born of the same parents fall off, and count 1 × 105A/ml, is made cell suspension；
2) take cell suspension inoculation on 96 orifice plates, 100 holes μ l/ set 37 DEG C of constant temperature, 5%CO2It is cultivated 24 hours in incubator；
3) various concentration test medicine, 10 holes μ l/ (final concentration of: 2,5,10 μM) is added in administration group, and 2 holes μ l/ are added in positive group
(final concentration of: 200 μM) vitamin E；Culture 24 hours；
4) 10 μ l culture solutions are added in the every hole of control group, and model group, positive group, the every hole of administration group are separately added into 10 μ l final concentration, 100 μ
The t-BHP of M, is incubated for 6h in the incubator；
5) CCK-8 of 10 μ l is added in every hole, is incubated for 1h in the incubator；
6) it being measured with microplate reader, measurement wavelength is 450nm, calculate vigor:
Vigor=100%- [A (control)-A (sample)]/[A (control)-A (blank)] × 100%；
As a result (n=3) are indicated with each laboratory mean values ± S.D..
Experimental result:
Compared with the control group,#P < 0.01 has significant difference.Compared with model group, * P < 0.05, * * P < 0.01 have
Significant difference.
The experimental results showed that NSC34 cell viability can be improved in compound 1 and the high, medium and low dosage group of compound 2, it is right
NSC34 cell has protective effect.
It is horizontal that 1.3 streaming methods detect cell ROS
Experimental method:
1) the NSC34 cell in good condition in exponential phase of growth is taken, addition 0.25% tryptic digestive juice digestion makes adherent thin
Born of the same parents fall off, and count 106A/ml, is made cell suspension；
2) take cell suspension inoculation on 24 orifice plates, 500 holes μ l/ set 37 DEG C of constant temperature, 5%CO2It is cultivated 24 hours in incubator；
3) various concentration test medicine, (final concentration of: 2,5, the 10 μM) culture in 100 holes μ l/ 24 hours is added in administration group；It is positive
(final concentration of: the 200 μM) culture of 10 hole μ l/ vitamin Es 24 hours is added in group；
4) 10 μ l culture solutions are added in the every hole of control group, and model group, positive group, the every hole of administration group are separately added into 10 μ l final concentration, 200 μ
The t-BHP of M, is incubated for 0.5h in the incubator；
5) CellROX reagent is added in every hole, final concentration of 5 μM, is incubated for 0.5h in the incubator；It is cleaned 2 times with PBS later；
6) 0.25% tryptic digestive juice is added, collects cell, 500 μ l PBS are added, cell suspension is made；
7) with flow cytometer measurement 105A cell, Detection wavelength 670nm；
The experimental result of ROS fluorescence intensity is as follows:
Compared with the control group, P < 0.01 #；Compared with model group, P < 0.01 *
The result shows that: compound 1 and compound 2 can significantly reduce the intracellular ROS fluorescence intensity of NSC34, have to NSC34 cell
There is anti-oxidation protection effect.
1.4 intracellular ROS imagings
Experimental method:
Step 1) -5) with above-mentioned 1.3 step 1) -5)；
6) the fixed 15min of 4% paraformaldehyde is added, siphons away paraformaldehyde, is cleaned 2 times with PBS, it is final concentration of to add 300 μ l
10 μ g/ml Heochest33342 cultivate 10min, siphon away, cleaned 2 times later with PBS；
7) film-making is made film with confocal microscopy.
Experimental result:
The result is shown in Figure 13, blue represent nucleus, and red represents ROS intracellular.It is compared with model group, the intracellular ROS of administration group is red
Color fluorescence intensity significantly reduces, and shows that compound 1 and compound 2 inhibit t-BHP induction NSC34 cell to generate ROS, it was demonstrated that have
Antioxidation.
1.5 apoptosis rate
Method: cell culture processes are with " 1.2 ", and detection method is dyed using Annexin V-FITC apoptosis and detection kit
(abcam, USA) detects apoptosis rate；Specific experiment operation refers to kit specification.Experimental result see the table below.
Compared with the control group,# P<0.01；Compared with model group, *P<0.05
The result shows that: compound 1 and compound 2 can significantly reduce NSC34 apoptosis rate.
In summary it can be seen: the present invention includes Oleanolic triterpenic glycoside class compound and/or benzene acetonitrile glycoside chemical combination
The seed of feather cockscomb effective component of object has good protective effect, specific manifestation to t-BHP inducing nerve cell NSC34 damage model
For acellular poison toxicity, cell viability is improved, reduces intracellular ROS level, reduces apoptosis rate.
Claims (5)
1. seed of feather cockscomb effective component, which is characterized in that including Oleanolic triterpenic glycoside class compound and/or benzene acetonitrile glycoside
The structural formula of compound, Oleanolic triterpenic glycoside class compound is as follows:
；
The structural formula of benzene acetonitrile glycosides compound is as follows:
。
2. the preparation method of seed of feather cockscomb effective component described in claim 1, which comprises the steps of:
1) seed of feather cockscomb that crushed or the stir-fry seed of feather cockscomb are subjected to homogenate extraction with 20-50% ethyl alcohol, extracting solution is concentrated to get extraction
Object medicinal extract；Extract medicinal extract is dispersed in water, is adsorbed with macroporous absorbent resin, water, 20% ethyl alcohol and 60% second are then successively used
Alcohol gradient elution collects 20% ethanol eluate, solvent is recovered under reduced pressure, obtains 20% ethanol extract A；60% ethanol eluate is collected,
Solvent is recovered under reduced pressure, obtains 60% ethanol extract B；
2) by 20% ethanol extract A through thin-layer chromatography silica gel column chromatography, select volume ratio 8:1 methylene chloride and methanol solvate into
Row elution, recycling design obtain flow point；HPLC chromatogram method is partly prepared again, is eluted with 20% methanol-water, and retention time is
24min obtains benzene acetonitrile glycosides compound；
3) 60% ethanol extract B is selected into methanol-water solvent system, successively respectively with 15% first through the open column of MCIGELCHP20
Alcohol, 40% methanol, 50% methanol, 60% methanol, 100% methanol elution gradient, obtained component are successively denoted as: B-1, B-2, B-3, B-
4,B-5；By component B-5 through thin-layer chromatography silica gel column chromatography, the methylene chloride of volume ratio 5:1 and methanol solvate is selected to be washed
It takes off to get Oleanolic triterpenic glycoside class compound.
3. the preparation method of seed of feather cockscomb effective component as claimed in claim 2, which is characterized in that in step 1), homogenate extraction 2-
3 times, when homogenate extraction, or fries the 20-50% ethyl alcohol of seed of feather cockscomb addition 5-10mL at every 1 g seed of feather cockscomb, each homogenate extraction when
Between be 3-10min.
4. application of the seed of feather cockscomb effective component in terms of preparing nerve protection medicine or health care product described in claim 1.
5. seed of feather cockscomb effective component described in claim 1 is in terms of preparation treatment neurodegenerative disease drug or health care product
Using.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910572816.4A CN110204589B (en) | 2019-06-28 | 2019-06-28 | Effective component of feather cockscomb seed, extraction method and application thereof in preparing neuroprotective medicament |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910572816.4A CN110204589B (en) | 2019-06-28 | 2019-06-28 | Effective component of feather cockscomb seed, extraction method and application thereof in preparing neuroprotective medicament |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110204589A true CN110204589A (en) | 2019-09-06 |
| CN110204589B CN110204589B (en) | 2021-04-09 |
Family
ID=67795236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910572816.4A Active CN110204589B (en) | 2019-06-28 | 2019-06-28 | Effective component of feather cockscomb seed, extraction method and application thereof in preparing neuroprotective medicament |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110204589B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114452310A (en) * | 2020-11-10 | 2022-05-10 | 苏州禾研生物技术有限公司 | Plant extract for preventing novel coronavirus infection and preparation method and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1850836A (en) * | 2006-05-23 | 2006-10-25 | 中国人民解放军第二军医大学 | Celosia argentea suponin compound and its pharmaceutical use |
| CN104387438A (en) * | 2014-10-27 | 2015-03-04 | 中国药科大学 | Novel triterpene saponin compound celosin L seperated from seeds of celosia argentea and medicinal uses of celosin L |
| CN108017681A (en) * | 2016-11-04 | 2018-05-11 | 云南巅青生物科技有限公司 | O- aryl glycosides derivative, its pharmaceutical composition and application |
| CN109734769A (en) * | 2019-02-14 | 2019-05-10 | 沈阳化工大学 | With active six triterpene saponin componds of neurocyte protection |
-
2019
- 2019-06-28 CN CN201910572816.4A patent/CN110204589B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1850836A (en) * | 2006-05-23 | 2006-10-25 | 中国人民解放军第二军医大学 | Celosia argentea suponin compound and its pharmaceutical use |
| CN104387438A (en) * | 2014-10-27 | 2015-03-04 | 中国药科大学 | Novel triterpene saponin compound celosin L seperated from seeds of celosia argentea and medicinal uses of celosin L |
| CN108017681A (en) * | 2016-11-04 | 2018-05-11 | 云南巅青生物科技有限公司 | O- aryl glycosides derivative, its pharmaceutical composition and application |
| CN109734769A (en) * | 2019-02-14 | 2019-05-10 | 沈阳化工大学 | With active six triterpene saponin componds of neurocyte protection |
Non-Patent Citations (5)
| Title |
|---|
| NUAN MA ET AL.: "Three Constituents of Moringa oleifera Seeds Regulate Expression of Th17-Relevant Cytokines and Ameliorate TPA-Induced Psoriasis-Like Skin Lesions in Mice", 《MOLECULES》 * |
| YING TANG ET AL.: "Review on research of the phytochemistry and pharmacological activities of Celosia argentea", 《REVISTA BRASILEIRA DE FARMACOGNOSIA》 * |
| YUANYUAN CHENG ET AL.: "Proteomic identification of calcium-binding chaperone calreticulin as a potential mediator for the neuroprotective and neuritogenic activities of fruit-derived glycoside amygdalin", 《JOURNAL OF NUTRITIONAL BIOCHEMISTRY》 * |
| YUKA KOIKE ET AL.: "Novel phenolic glycosides, adenophorasides A-E, from Adenophora roots", 《J NAT MED》 * |
| 沈姗: "青葙子炒品化学成分及质量标准的研究", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114452310A (en) * | 2020-11-10 | 2022-05-10 | 苏州禾研生物技术有限公司 | Plant extract for preventing novel coronavirus infection and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110204589B (en) | 2021-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Qi et al. | Chemical constituents from leaves of Camellia nitidissima and their potential cytotoxicity on SGC7901 cells | |
| Barbosa et al. | Determination of myricetin derivatives in Chrysobalanus icaco L.(Chrysobalanaceae) | |
| Sung et al. | Bioassay-guided isolation of anti-adipogenic compounds from defatted pepper (Capsicum annuum L.) seeds | |
| CN110204589A (en) | Seed of feather cockscomb effective component, extracting method and its application in terms of preparing nerve protection medicine | |
| CN104761596A (en) | Method for preparing anthocyanin standard substance | |
| Maza et al. | Triterpenoids from seeds of Tapinanthus bangwensis | |
| Aboalola et al. | Toxicological study of various crude extracts of Hyoscyamus gallagheri native to Oman | |
| CN111440157B (en) | Method for simultaneously separating schaftoside, vitamin adopted-2 and ecdysone and application thereof | |
| CN105524063A (en) | Novel terpene indole alkaloid compound, and preparation method and medical application thereof | |
| CN105566427A (en) | Lanostane triterpene compound, and preparation method and medicinal use thereof | |
| CN106928309A (en) | A kind of spirosolane type glycoalkaloid and preparation method thereof and purposes | |
| CN105837595A (en) | Medicinal composition of atenolol and application of medicinal composition in biological medicine | |
| CN105820208A (en) | Novel withanolide compound and preparation method and medical application thereof | |
| CN106939031B (en) | A kind of spirosolane type glycoalkaloid and preparation method thereof and purposes | |
| CN109422651A (en) | Decahydronaphthalenes and application thereof | |
| Schmidt et al. | New triterpene esters from flowerheads of Arnica lonchophylla | |
| CN105669793B (en) | Oleanane-type triterpene saponin class compound, preparation method and its application | |
| Zou et al. | Fractionation, identification and biological activities of ethanol extract of kuding tea (Ilex latifolia Thunb.). | |
| Maridass et al. | Investigation of phytochemical constituents from Eulophia epidendraea | |
| Li et al. | Application of high-speed counter-current chromatography for isolation of triterpenes from Schisandra chinensis (Turcz.) Baill and induction apoptosis mechanism of HSC-T6 | |
| KR20110087395A (en) | A composition comprising pseurotin d as an active ingredient for treating and preventing cancer disease | |
| CN106946973B (en) | A kind of compound and preparation method thereof, purposes | |
| Nguyen | Valorization of natural drug products: from extraction to encapsulation | |
| KR20110087397A (en) | A composition comprising isodihydroauroglaucin as an active ingredient for treating and preventing cancer disease | |
| Sun et al. | NF-${\kappa} B $ Inhibitory Activities of Phenolic and Lignan Components from the Stems of Acanthopanax divaricatus var. albeofructus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |